Summary
To assess the feasibility and toxicity profile of high-dose interferon alpha-2b (IFN-α-2b) in the adjuvant treatment of patients with cutaneous malignant melanoma outside the reference ECOG 1684 clinical trial, we conducted a prospective follow-up in an identical population of patients (cutaneous melanoma, T4 and/or N1) treated by intravenous IFN-α-2b:20 MIU m–2, 5 days a week for 4 weeks; and subcutaneous:10 MIU m–2, 3 times a week for 11 months. Thirty-six consecutive patients were considered in four different institutions. The frequency and severity of side-effects related to IFN-α, as well as the percentage of the planned dose given to patients, were identical to those reported in the initial report by ECOG. Fifty per cent and 47% of patients had a grade 3/4 WHO toxicity in the induction and consolidation phase respectively. A dose modification was necessary for 47.2% and 55.8% of the patients in the induction and consolidation phase respectively. The schedule and dose of high-dose IFN-α-2b in the adjuvant treatment of cutaneous malignant melanoma, as reported by ECOG 1684, is feasible. The significant toxicity reported in ECOG 1684 was also seen in our patients. Nevertheless, this protocol will not be a ‘standard’ treatment until the publication of the ECOG 1690 trial.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Cole, B. F., Gelber, R. D., Kirkwood, J. M., Goldhirsch, A., Barylak, E. & Borden, E. (1996). Quality-of-life adjusted survival analysis of interferon alpha-2b adjuvant treatment of high-risk cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 14: 2666–2673.
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C. & Blum, R. H. (1996). Interferon alpha-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14: 7–17.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ravaud, A., Bedane, C., Geoffrois, L. et al. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. Br J Cancer 80, 1767–1769 (1999). https://doi.org/10.1038/sj.bjc.6690595
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690595
Keywords
This article is cited by
-
Adjuvant interferon in the treatment of melanoma
British Journal of Cancer (1999)